Quarterly ResultMay 7, 2026, 04:20 PM
Guardant Health Q1 Revenue +48% to $301.7M; Raises 2026 Guidance
AI Summary
Guardant Health reported strong first-quarter 2026 financial results, with total revenue increasing 48% year-over-year to $301.7 million. This growth was driven by significant increases in Oncology revenue (+36%) and Screening revenue (over 600%). The company also raised its full-year 2026 revenue guidance to $1.30 to $1.32 billion, representing 32% to 34% growth, up from prior guidance. Operating highlights included FDA approval for Guardant360 CDx and new collaborations.
Key Highlights
- Total revenue $301.7M, up 48% YoY in Q1 2026.
- Oncology revenue $205.0M, up 36%; 86,000 tests, up 47%.
- Screening revenue $41.6M, up over 600%; 44,000 tests.
- Non-GAAP gross margin 66% in Q1 2026, up from 65%.
- Net loss $112.1M ($0.85 per share) in Q1 2026.
- Raises 2026 revenue guidance to $1.30-$1.32B (+32-34%).
- Oncology revenue 2026 guidance raised to 28-29% growth.
- Screening revenue 2026 guidance raised to $186-$198M.